News
Genus plc Reports Interim First Half 2021 Fiscal Year Results
Genus plc (LSE: GNS), a global biotechnology leader in animal genetics, today reported interim results for the six-months period ending December 31, 2020, as well as provided a business update on
LivaNova Reports Fourth Quarter and Full-Year 2020 Results
LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full-year ended December 31, 2020.
For the fourth quarter of
LivaNova to Host Conference Call for Fourth Quarter and Full-Year 2020 Results
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its fourth quarter and full-year 2020 results on Wednesday, February
Genus plc Provides Update on Financial Performance for First Half of Fiscal 2021
Genus plc (LSE: GNS), a global biotechnology leader in animal genetics, today reported continued strong performance across its operations for the six-months period ending December 31, 2020.
The
LivaNova Announces Board Appointment and Board Leadership Changes
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced a series of enhancements to the Company’s governance.
Todd Schermerhorn has been appointed
LivaNova und Gyrus Capital schließen Vereinbarung über den Kauf des Herzklappengeschäfts
LivaNova PLC (NASDAQ:LIVN), ein marktführendes Medizintechnik- und Innovationsunternehmen, und Gyrus Capital (Gyrus), eine Investmentfirma, die sich auf Investitionen im Gesundheits- und
LivaNova to Host Satellite Symposium on Advances in Neuromodulation at American Epilepsy Society AES2020 Virtual Event
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it will host “Updates and Advances in Neuromodulation,” a satellite symposium at AES2020, the
LivaNova and Gyrus Capital Enter into Agreement for the Purchase of Heart Valve Business
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, and Gyrus Capital (Gyrus), an investment firm dedicated to investments in the healthcare and sustainability
Clinigen Launches Malaysia Office to Strengthen Presence in Southeast Asia
Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, has launched its Malaysian business with an office in Kuala Lumpur. The new office is part of Clinigen’s
LivaNova to Present at the Berenberg European Conference 2020
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Damien McDonald, Chief Executive Officer, will participate in discussions at the Berenberg European
Genus plc Provides Update on Fiscal 2021 Financial Performance
Genus plc (LSE: GNS), a global biotechnology leader in animal genetics, today reported continued strong performance across its operations for the period from July 1, 2020 through November 24, 2020
Clinigen Expands Partnership With Accord Healthcare in Clinical Services Into France
Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, announces that its Clinical Services (CS) business has expanded its exclusive ’on-demand’ supply service
LivaNova to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Damien McDonald, Chief Executive Officer, will participate in discussions at the Piper Sandler 32nd Annual
LivaNova to Present at the Stifel 2020 Virtual Healthcare Conference
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced Damien McDonald, Chief Executive Officer, will present at the Stifel 2020 Virtual Healthcare
LivaNova Reports Third Quarter 2020 Results
LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended September 30, 2020.
For the third quarter of 2020, worldwide
LivaNova präsentiert auf der Jahrestagung der European Association for Cardio-Thoracic Surgery neue Daten zur Demonstration der Vorteile der nahtlosen Percevalklappe
LivaNova PLC (NASDAQ:LIVN), ein marktführendes Medizintechnik- und Innovationsunternehmen, gab heute neue Daten aus der klinischen Studie über Perceval®, dem nahtlosen Implantat im Vergleich zum
LivaNova Confirms Receipt of Letter from PrimeStone Capital
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today confirmed receipt of a letter from PrimeStone Capital LLP (PrimeStone) to its Board of Directors and
LivaNova Presents New Data at European Association for Cardio-Thoracic Surgery Annual Meeting Demonstrating Benefits of Perceval Sutureless Valve
LivaNova PLC (NASDAQ:LIVN) a market-leading medical technology and innovation company, today announced new data from the Perceval® Sutureless Implant Versus Standard-Aortic Valve Replacement
LivaNova to Host Conference Call for Third Quarter 2020 Results
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its third quarter 2020 results on Thursday, October 29, 2020 at 12
LivaNova to Present at the Baird 2020 Global Healthcare Conference
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced Damien McDonald, Chief Executive Officer, will present at the Baird 2020 Global Healthcare
LivaNova to Present Autonomic Regulation Therapy Findings for Heart Failure During European Society of Cardiology Congress 2020
LivaNova PLC (NASDAQ:LIVN) a market-leading medical technology and innovation company, today announced it will present a poster at the European Society of Cardiology (ESC) Congress 2020 on the
FDA Approves GSK’s BLENREP (belantamab mafodotin-blmf) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
GlaxoSmithKline plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has approved BLENREP (belantamab mafodotin-blmf) as a monotherapy treatment for adult patients with relapsed
LivaNova Reports Second Quarter 2020 Results
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended June 30, 2020.
For the second quarter of 2020, worldwide sales
LivaNova kündigt die kommerzielle Markteinführung der Aorten-Herzklappe Perceval Plus in Europa an
LivaNova PLC (NASDAQ:LIVN), ein marktführendes Medizintechnik- und Innovationsunternehmen, gab heute bekannt, dass die fortschrittliche nahtlos-chirurgische Aorten-Herzklappe Perceval® Plus jetzt
LivaNova Announces Commercial Launch of Perceval Plus Aortic Heart Valve in Europe
LivaNova PLC (NASDAQ:LIVN) a market-leading medical technology and innovation company, today announced that the advanced Perceval® Plus sutureless surgical aortic heart valve is now available for